قالب وردپرس درنا توس
Home / Business / Big Bristol-Myers Shareholder Opposes Celgene Deal

Big Bristol-Myers Shareholder Opposes Celgene Deal



One of Bristol-Myers Squibb Cos's largest shareholders opposes the company's $ 74 billion deal to buy rival Celgene Corp., and becomes the last investor to express their unhappiness with the transaction.

Wellington Management Co., an investment company with a stake of around 8% in Bristol-Myers, said Wednesday that the deal was asking shareholders to take too much risk and offering Bristol shares for cheap to Celgene shareholders. The company also said it was more difficult to complete a successful transaction than management expected.


Source link